Surmodics, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenue to range from $116 million to $121 million, representing a decrease of (13)% to (9)% compared to fiscal 2023. The company expects fiscal 2024 GAAP diluted loss per share to range from $1.55 to $1.20.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.16 USD | -0.50% | -1.02% | -11.53% |
May. 02 | Barrington Ups Price Target on SurModics to $71 From $70, Maintains Outperform Rating | MT |
May. 01 | Top Midday Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.53% | 459M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+3.43% | 26.53B | |
+13.67% | 25.02B | |
-0.32% | 24.96B |
- Stock Market
- Equities
- SRDX Stock
- News Surmodics, Inc.
- Surmodics, Inc. Provides Earnings Guidance for the Year 2024